Short-term renal and cardiac outcomes of combined ARNI and SGLT2 therapy in AHF patients: a prospective single-arm interventional study
-
By
-
May 1, 2026
-
1
The study enrolled 120 AHF patients with LVEF ≤40% to evaluate combined ARNI and SGLT2 inhibitor therapy post-hemodynamic stabilization.
-
2
Significant increases in urine volume and diuretic response were observed on day 1, stabilizing above baseline levels during the study.
-
3
Cardiovascular biomarkers improved, with decreased NT-proBNP levels and increased LVEF, while eGFR remained unaffected.
-
4
The findings suggest potential benefits of combined ARNI and SGLT2 inhibitor therapy in AHF management, warranting further randomized trials.
-
5
Limitations include the short-term nature of the study and absence of a control group, hindering definitive causal attribution of effects.